Braidwell’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Braidwell’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-277,778	Closed	-$6.17M	–	90
2023 Q3	$6.17M	Buy	+277,778	New	+$5.83M	0.19%	83

Other funds holding RYZB

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell's RYZB Position: Q4 2023 in Review

Braidwell sold out of RayzeBio, Inc. Common Stock (RYZB) in Q4 2023, closing a stake of 277,778 shares — an estimated $6.17M sold.

Braidwell first reported a position in RYZB in Q3 2023 and held it in 1 quarter. The position peaked at $6.17M in Q3 2023. 107 funds tracked by Wall St. Rank hold RYZB as of Q4 2023.

Braidwell reported no remaining RayzeBio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Braidwell sold 277,778 RayzeBio, Inc. Common Stock shares in Q4 2023, an estimated $6.17M.
Braidwell first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
Braidwell's RayzeBio, Inc. Common Stock position peaked at $6.17M in Q3 2023.
107 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q4 2023.

Based on Braidwell's 13F filing for Q4 2023, filed 14 Feb 2024.